BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35359852)

  • 1. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
    Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
    Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
    Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
    Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
    Matsuno O; Minamoto S
    Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
    Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
    Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
    N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
    Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
    Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
    Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
    Menzella F; Galeone C; Ghidoni G; Ruggiero P; Capobelli S; Simonazzi A; Catellani C; Scelfo C; Livrieri F; Facciolongo N
    Multidiscip Respir Med; 2021 Jan; 16(1):779. PubMed ID: 34221399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
    Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
    Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
    Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
    Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benralizumab in the management of rare primary eosinophilic lung diseases.
    Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
    Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
    Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
    Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
    BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
    Sugiyama T; Yoshida S; Kikuchi S; Iino Y
    Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
    Carrette A; Mercier V; Lelubre C; Peché R
    Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
    Kouverianos I; Angelopoulos A; Daoussis D
    Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab for eosinophilic granulomatosis with polyangiitis.
    Cottu A; Groh M; Desaintjean C; Marchand-Adam S; Guillevin L; Puechal X; Beaumesnil S; Lazaro E; Samson M; Taille C; Durel CA; Diot E; Nicolas S; Guilleminault L; Ebbo M; Cathebras P; Dupin C; Yildiz H; Belfeki N; Pugnet G; Chauvin P; Jouneau S; Lifermann F; Martellosio JP; Cottin V; Terrier B;
    Ann Rheum Dis; 2023 Dec; 82(12):1580-1586. PubMed ID: 37550002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
    Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
    ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab.
    Kai Y; Yoshikawa M; Matsuda M; Suzuki K; Ohara H; Iguchi N; Kasamatsu T; Uno K; Fujioka N; Fujita Y; Muro S
    Allergy Asthma Clin Immunol; 2022 Feb; 18(1):14. PubMed ID: 35183225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.